ProCare Rx Appoints John Drakulich as President of their PBM Business

ProCare Rx • May 6, 2025

ProCare Rx Appoints John Drakulich as President of their PBM Business

  • This appointment brings together multiple parts of the business under one umbrella to best serve our PBM clients and members, assuring that ClearSight transparency and Lowest Net Cost remains at the forefront of the innovative organization.


Gainesville, GA, May 5, 2025 - ProCare Rx is proud to announce John Drakulich has been named President of their PBM business group. An experienced industry leader, John will assume responsibilities on May 19th. This role was created as the 38-year-old firm re-organizes to best serve their clients.


“We are proud to welcome John to the ProCare Rx leadership team,” said Barbara Rambo, CEO/CFO of ProCare Rx. “He is a respected and visionary leader in the PBM industry, with a demonstrated ability to drive growth and innovation. His breadth of experience across key markets—commercial employers, payers, government, hospitals, health systems, labor groups and other carve out programs—aligns perfectly with our strategic direction. John's leadership will be instrumental as we continue to deliver value and advance our mission.”


Drakulich was previously at RxSense as the Senior Vice President of Health Plan Sales, and prior to that he held various executive roles in Sales and Operations with OptumRx, Prime Therapeutics, Anthem, PCS Advance, and ValueRx.  His responsibilities included sales strategy, operational transparency, PBM sales, value proposition, and leveraging cross functional leadership across organization to gain buy-in and support for highly profitable production. His efforts have delivered substantial increases in new revenue, and lives.


“I’m honored to join ProCare Rx at such a pivotal time in its journey,” said John Drakulich President of ProCare Rx’s PBM line of business. “The company has a strong foundation and a clear vision; one we will build upon by rendering innovative strategies and products that enhance our differentiation and deepen the value we deliver to clients.  With over 3 decades in the PBM space, I understand the complexity and opportunity in this industry, and I am excited to lead a team so deeply committed to redefining what pharmacy benefit management can achieve.”


“John brings a long and diverse history of innovation that has consistently driven strategic differentiation and sharpened organizational focus,” said Barbara Rambo, CEO/CFO of ProCare Rx. “With decades of experience in the PBM industry, he has a deep understanding of pharmacy financials and the underwriting of pharmacy products and services. His insight and leadership will play a critical role in strengthening our market position and refining our value proposition as we enter our next phase of growth.”


John is a graduate of the University of Colorado – Denver where he earned a BS in Business, Management, Marketing, and Related Support Services. While he anticipates continuing to leverage his home base in Minneapolis, MN where he resides with his family, he will dedicate considerable time with the key ProCare Rx team members, clients, and prospects across multiple locations



About ProCare Rx
ProCare Rx is a privately held, independent pharmacy benefit manager (PBM) that has empowered healthcare and self-insured organizations since 1988. We provide fully integrated, in-house solutions—including claims adjudication, clinical program design, pharmacy network access, cost containment, and data analytics—all supported in the U.S. Our flexible, transparent model serves self-insured employers, third-party administrators (TPA), brokers, health plans, health systems, managed care organizations (MCO), unions, workers’ compensation programs, Medicare, Medicaid, hospices, and other PBMs. With a proprietary technology platform, commitment to ethical operations, and a focus on lowest net cost, ProCare Rx delivers long-term value, clinical performance, and trusted pharmacy benefit partnerships.

Media Contact:
Marc Cohen, VP, Marketing and Sales
marketing@ProCareRx.com

By ProCare Rx Team August 5, 2025
When Courts and Care Collide: What the Arkansas PBM Ruling Means for the Industry
By ProCare Rx Team July 8, 2025
Prescription Drug Pricing: Will Policy Fix What Patients Feel?
By ProCare Rx Team June 2, 2025
Is Your PBM Working for You…Or Against You? How to Ask the Right Questions and Spot Red Flags in Pharmacy Benefit Management
By ProCare Rx May 20, 2025
ProCare Rx Announces New Executive Appointment and Launch of Technology Division to Drive Innovation and Growth The newly created role is expected to solidify leadership of the core technology infrastructure to both enhance support for current clients as well as developing additional value-added offerings to the marketplace.
By ProCare Rx Team May 19, 2025
Understanding the “Most Favored Nation” Drug Pricing Rule
By ProCare Rx Team May 19, 2025
ProCare Rx's Innovative Approach to Pharmacy Benefit Management
By ProCare Rx Team April 21, 2025
ProCare Rx’s ProCare PharmacyCare, LLC Earns URAC Accreditation in Specialty Pharmacy
By ProCare Rx Team April 15, 2025
Prescription Drug Reform Gains Momentum: What the New Senate Bill Means for Plan Sponsors
By ProCare Rx Team April 2, 2025
The White House recently launched the Make America Healthy Again Commission to address some of the biggest challenges in U.S. healthcare—including chronic disease, medication reliance, and drug safety. While the full impact remains to be seen, this initiative signals potential shifts in how prescription drugs are evaluated, priced, and prescribed. For plan sponsors, employers, and pharmacy benefits managers (PBMs), the key question is: How can we ensure medication access, affordability, and safety while staying ahead of possible regulatory changes? Reevaluating Medication Reliance One of the Commission’s focus areas is over-reliance on medication and treatments. This could lead to a push for more careful prescribing practices, increased scrutiny of high-cost drugs, and expanded support for alternative treatment methods. PBMs can play a proactive role by ensuring plan designs promote clinically effective, cost-conscious prescribing, including: Encouraging use of generics and biosimilars when available Implementing clinical programs that support appropriate prescribing Providing medication management resources to help members navigate treatment options Increased Attention on Drug Safety & Pricing The Commission also highlights food and drug quality and safety , reinforcing the need for greater transparency in pharmaceutical manufacturing and pricing . This could mean: Tighter regulations on imported medications and supply chain oversight More scrutiny on rebate structures and how drug prices are set A renewed focus on affordability strategies for plan sponsors and consumers For PBMs and health plans, transparent pricing models and clear rebate structures will be key to staying compliant and ensuring members have access to safe, fairly priced medications. Eliminating Conflicts of Interest in Health Research Another priority for the Commission is ensuring federally funded health research is free from conflicts of interest . This could impact how drug effectiveness is studied, how formularies are built, and how treatment guidelines are developed. Employers and health plans should work with PBMs that prioritize: Data-driven formulary management based on independent clinical outcomes Objective drug evaluations to balance cost and effectiveness Transparent partnerships with health providers and pharmaceutical companies What’s Next? The Make America Healthy Again Commission is still in its early stages, but its focus on medication reliance, drug safety, and pharmaceutical pricing should not be ignored. Employers and plan sponsors should be prepared for potential policy changes that could impact pharmacy benefits. By working with PBMs that prioritize clinical integrity, cost control, and member education , organizations can stay ahead of the curve and continue to provide high- quality, affordable healthcare solutions. Would you like to review your pharmacy benefits strategy? Let’s talk. Click the button below to learn more about ProCare Rx's Offering and signup to hear from one of our sales team.
By ProCare Rx Team March 3, 2025
FTC Report Reveals $7.3 Billion in Excessive PBM Revenues—What It Means for Employers and Patients